Novel therapeutic targets and drug discovery strategies in chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD) is a heterogeneous, progressive respiratory disorder characterized by a triad of airway remodeling, emphysema, and vascular dysfunction, posing a formidable therapeutic challenge and a leading global cause of morbidity and mortality. While current treatments, primarily long-acting bronchodilators and inhaled corticosteroids, provide symptomatic relief, they fail to halt disease progression or repair structural damage. This review aims to bridge the burgeoning understanding of COPD's complex pathophysiology with the development of next-generation, disease-modifying therapies by critically synthesizing emergent mechanistic targets, the evolving investigational pipeline, and novel concepts in therapeutic design. The unraveling of its intricate pathogenic mechanisms, encompassing dysregulated innate and adaptive immunity, newly appreciated neuro-immune crosstalk, cellular senescence, metabolic reprogramming, pro-inflammatory cell death modalities, protease-antiprotease imbalance, defective tissue repair, and persistent epigenetic modifications, is now spurring the development of precision medicine strategies, biomarker-guided patient stratification, and novel therapeutics, including biologics targeting type 2 inflammation, upstream alarmin blockades, multifunctional small molecules, balanced phosphodiesterase inhibitors, and regenerative approaches. Concurrently, innovative therapeutic modalities such as senescence-targeted interventions (senolytics) and nucleic acid-based therapies, coupled with advanced drug delivery systems including lung-targeted nanocarriers, are reshaping COPD pharmacotherapy. Future directions emphasize endotype-specific modulation, multi-pathway interventions, and integrated multidimensional endpoints to enable early intervention, improve trial success, and achieve long-term disease control with potential for structural recovery. Ultimately, this synthesis provides a forward-looking roadmap for translating deep mechanistic insights into clinically effective, disease-modifying therapies for COPD.